ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,393.80
0.85%
S&P ASX All Technology
3,840.60
-1.02%
Brent Oil
74.005
0.10%
US Dollar vs AUD
1.5408
0.30%
Bitcoin
99,203.80
0.70%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Belite Bio Inc (BLTE)

  7. Belite Bio Inc (BLTE) News

Belite Bio Inc

Belite Bio Inc (BLTE)

NASDAQ
82.45
-0.08
(-0.10%)
Closed 22 November 8:00AM
Delayed by 15 minutes
82.46
0.01
(0.01%)
After Hours: 11:59AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

BLTE News

Official News Only

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
21 November 2024
BLTE (-0.10%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
20 November 2024
BLTE (-0.10%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
04 November 2024
BLTE (-0.10%)

Form 144/A - Report of proposed sale of securities: [Amend]
Edgar (US Regulatory)
09 October 2024
BLTE (-0.10%)

Form 144/A - Report of proposed sale of securities: [Amend]
Edgar (US Regulatory)
09 October 2024
BLTE (-0.10%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
04 October 2024
BLTE (-0.10%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
04 October 2024
BLTE (-0.10%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
01 October 2024
BLTE (-0.10%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
21 September 2024
BLTE (-0.10%)

BLTE Discussion

View Posts
Monksdream Monksdream 2 months ago
BLTE will it break out
👍️0
conix conix 2 years ago
Short Interest for BLTE--Up 30%

https://www.etfdailynews.com/2022/09/17/short-interest-in-belite-bio-inc-nasdaqblte-expands-by-30-1/
👍️0
conix conix 2 years ago
BLTE News

https://seekingalpha.com/news/3875434-blte-stock-gains-as-pivotal-trial-for-lead-asset-starts-in-us
👍️0
conix conix 2 years ago
'Novel Approach For Retinal Disease Needs' Stock Belite Bio Has 70% Potential Upside According To This Analyst

Vandana Singh

Mon, August 1, 2022

HC Wainwright initiated coverage on Belite Bio Inc (NASDAQ: BLTE) with a Buy rating and price target of $58 per ADS.

Belite Bio is focused on developing a novel once-daily oral drug for the treatment of Stargardt disease (STGD1)—a rare inherited juvenile-onset form of macular degeneration.

The lead drug candidate is LBS-008 (or Tinlarebant).

HC Wainwright says that as LBS-008 is administered orally once a day, it could be adopted rapidly by ophthalmologists and patients once the drug obtains regulatory approval, as the intravitreal injection procedure was found unpleasant.

"We believe LBS-008 has the potential to be developed as the first and best-in-class oral drug for the treatment of STGD1," the analyst writes.

The analyst expects the Phase 2 portion to report 1-year data in 2H22.

Meanwhile, the company has initiated a Phase 3 trial of LBS-008 in adolescent STGD1 in 1H22, slated to enroll approximately 60 patients. Enrollment for Phase 3 trial to complete in mid-2023.
👍️0
conix conix 3 years ago
Belite Bio stock soars 65% in wake of strong IPO performance

May 03, 2022 12:30 PM ETBLTEBy: Val Kennedy, SA News Editor

IPO Initial Public Offering

Mikko Lemola/iStock via Getty Images

Belite Bio (BLTE) stock soared 65% on Tuesday on the heels of a strong performance last Friday following its $36M initial public offering.

Shares of the ophthalmology drug developer opened at $10.60, recently changing hands at $14.70, up 65%, at approximately $12.05 p.m. ET.

BLTE held its IPO on April 29, offering 6 million American Depositary Shares at $6 per ADS. Underwriters were granted an option to buy up to 900k additional shares ADSs at the public price. The company’s principal stockholder, Taiwan’s Lin BioScience, agreed to buy around $15M of the offering.

The stock rocketed following the IPO on Friday, reaching a session high of $17.50 before closing at $10.59, up 77% over its offering price. The stock slid 16% on Monday.

BLTE has been focused on developing treatments for eye and metabolic diseases. The company plans to use proceeds from the IPO in part to fund Phase 3 clinical testing for its drug candidate LBS-008 for Stargardt disease and further development of the product for the treatment of dry age-related macular degeneration.
👍️0
conix conix 3 years ago
Great news

https://www.morningstar.com/news/dow-jones/202205038965/belite-bio-shares-jump-47-after-fast-track-designation-for-lbs-008-treatment-for-stargardt-disease
👍️0

Your Recent History

NASDAQ
BLTE
Belite Bio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved